NEWS RELEASE

Biosensors To Distribute Mynx™ Vascular Closure Device In UK, Switzerland and France

Morges, Switzerland, 18 May 2011 – Biosensors International has announced an exclusive agreement with AccessClosure, Inc., the market segment leader in extravascular closure devices, for the distribution of the Mynx™ Vascular Closure Device throughout the UK, Switzerland and France. The extravascular Mynx device, designed for patient comfort while providing hemostasis without sutures or implants, will be sold as part of Biosensors' interventional cardiology product range. Biosensors has a well-established direct presence in the UK, Switzerland and France, and will provide AccessClosure with broad and rapid access to those markets.

"We are pleased to offer the Mynx device as part of our interventional cardiology product range" said Jeffrey B. Jump, CEO of Biosensors. "The Mynx device, paired with our portfolio of drug-eluting and bare-metal stents, allows us to offer a more complete solution to our customers. The Mynx has had great success in the United States and other international markets, and we anticipate similar success in these European countries."

"These European countries represent a meaningful market opportunity for us, and we are pleased to be able to partner with Biosensors' established sales force for the distribution of Mynx," added Gregory D. Casciaro, President and CEO of AccessClosure. "Distribution in international markets is a key component of AccessClosure's growth strategy, and provides an excellent complement to our direct sales presence in the United States."

The Mynx Vascular Closure Device utilizes a conformable, water-soluble polyethylene glycol (PEG) sealant to immediately seal the femoral artery. Dissolving within 30 days, Mynx leaves nothing behind but a healed artery. The extravascular device is designed for increased patient comfort and clinical versatility. The Mynx, which received its first FDA approval in May 2007, has been used in over 800,000 procedures to date.

-Ends-

For further information, please contact:

Corporate Communications
Richard Kenyon
Biosensors International
+44 7831569940
r.kenyon@biosensors.com

Investor Relations
Wong TeckYenn
Biosensors International Group
+65 6213 5708
ty.wong@biosensors.com

About Biosensors International

Biosensors International develops, manufactures and markets innovative medical devices for interventional cardiology and critical care procedures. We aim to improve patients' lives through pioneering medical technology that pushes forward the boundaries of innovation.

With the increasing use of the BioMatrix™ family of drug-eluting stents, we are rapidly emerging as a leader in the global coronary stent market. The forthcoming launch ofthe Axxess™ self-expanding bifurcation drug-eluting stent and the development of the BioFreedom™ drug-coated stent will further reinforce our market position.

All three stents incorporate Biolimus A9™ (BA9™), an anti-restenotic drug developed and patented by Biosensors specifically for use with drug-eluting stents. Both the BioMatrix stent family and the Axxess stent feature a unique abluminal biodegradable polymer coating, which fully degrades into carbon dioxide and water over a six-to-nine-month period as it releases BA9. The BioMatrix stent family features workhorse stent platforms for a broad range of lesions, and the Axxess stent employs a self-expanding stent platform specifically designed for treating bifurcation lesions. BioFreedom, a completely polymer□free stent abluminally coated with BA9, is currently undergoing clinical evaluation.

For more information, please visit www.biosensors.com.